458 related articles for article (PubMed ID: 26822204)
1. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
McLean LP; Cross RK
Expert Opin Investig Drugs; 2016; 25(3):263-73. PubMed ID: 26822204
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
3. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
Hagan M; Cross RK
Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
[TBL] [Abstract][Full Text] [Related]
4. [Vedolizumab in the treatment of Crohn's disease].
Gisbert JP; Domènech E
Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
[TBL] [Abstract][Full Text] [Related]
5. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
[TBL] [Abstract][Full Text] [Related]
6. The role of integrin antagonists in the treatment of inflammatory bowel disease.
Beniwal-Patel P; Saha S
Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab in the treatment of Crohn's disease.
Tarabar D; Hirsch A; Rubin DT
Expert Rev Gastroenterol Hepatol; 2016; 10(3):283-90. PubMed ID: 26810276
[TBL] [Abstract][Full Text] [Related]
8. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
9. The safety of vedolizumab for the treatment of ulcerative colitis.
Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
[TBL] [Abstract][Full Text] [Related]
10. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab for Crohn's disease.
Mosli MH; Feagan BG
Expert Opin Biol Ther; 2013 Mar; 13(3):455-63. PubMed ID: 23394379
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab in the treatment of Crohn's disease patients.
Pagnini C; Arseneau KO; Cominelli F
Expert Opin Biol Ther; 2017 Nov; 17(11):1433-1438. PubMed ID: 28832222
[TBL] [Abstract][Full Text] [Related]
13. Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease.
Shivashankar R; Pardi DS
Gastroenterol Clin North Am; 2017 Sep; 46(3):589-601. PubMed ID: 28838417
[TBL] [Abstract][Full Text] [Related]
14. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis.
Chandar AK; Singh S; Murad MH; Peyrin-Biroulet L; Loftus EV
Inflamm Bowel Dis; 2015 Jul; 21(7):1695-708. PubMed ID: 25856769
[TBL] [Abstract][Full Text] [Related]
16. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.
Allocca M; Gilardi D; Fiorino G; Furfaro F; Argollo M; Peyrin-Biroulet L; Danese S
Expert Opin Investig Drugs; 2018 Jul; 27(7):623-629. PubMed ID: 29985060
[TBL] [Abstract][Full Text] [Related]
17. Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis.
Poulakos M; Machin JD; Pauly J; Grace Y
J Pharm Pract; 2016 Oct; 29(5):503-15. PubMed ID: 25952593
[TBL] [Abstract][Full Text] [Related]
18. Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?
Khanna R; Mosli MH; Feagan BG
Dig Dis; 2016; 34(1-2):153-9. PubMed ID: 26982012
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
Saruta M; Papadakis KA
Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
[TBL] [Abstract][Full Text] [Related]
20. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.
Sandborn WJ; Vermeire S; Tyrrell H; Hassanali A; Lacey S; Tole S; Tatro AR;
Adv Ther; 2020 Jul; 37(7):3417-3431. PubMed ID: 32445184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
